TGFB1 and Hepatic fibrosis: Our research confirms the combination of drugs that inhibits oxidative stress in vivo, reduces hepatocyte damage and blocks the TGF-β1/Smad pathway to reduce ECM deposition will more effectively solve hepatic fibrosis.